Data as of Jan 23
| +0.40 / +1.79%|
The 9 analysts offering 12-month price forecasts for Celldex Therapeutics Inc have a median target of 33.00, with a high estimate of 45.00 and a low estimate of 24.00. The median estimate represents a +45.05% increase from the last price of 22.75.
The current consensus among 9 polled investment analysts is to Buy stock in Celldex Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.